Patents Examined by Jennifer S Spence
-
Patent number: 11981933Abstract: Devices, systems, and techniques are described for printing pre-aligned microtissues into larger tissue constructs. For example, a method of printing a tissue construct includes aligning cells in a first direction to create pre-aligned microtissues, suspending the pre-aligned microtissues in a liquid to create a bioink, and depositing the pre-aligned microtissues in a second direction to create the tissue construct.Type: GrantFiled: August 31, 2021Date of Patent: May 14, 2024Assignee: Regents of the University of MinnesotaInventors: Caleb Darwin Vogt, Angela Panoskaltsis-Mortari
-
Patent number: 11976297Abstract: The present disclosure provides engineered immune cells and methods for their creation and use. The immune cells comprise activating and blocking receptors, that exhibit cross-talk between the receptors.Type: GrantFiled: September 21, 2021Date of Patent: May 7, 2024Assignee: A2 BIOTHERAPEUTICS, INC.Inventor: Alexander Kamb
-
Patent number: 11970713Abstract: The invention relates to a method for long-term ex vivo maintenance or expansion of one or more of a human erythroblast, a human megakaryocyte-erythroid progenitor, or a human common myeloid progenitor, comprising the step of: culturing cells comprising one or more of those cells in a culture medium comprising one or more selected from a tankyrase inhibitor, a growth factor, a B-Raf kinase inhibitor and a GSK-3 inhibitor.Type: GrantFiled: December 2, 2021Date of Patent: April 30, 2024Assignee: OCGENE THERAPEUTICS CORPORATIONInventors: Chang Tong, Yibin Lin, Kangtao Lv
-
Patent number: 11946070Abstract: The present invention relates to a medium composition for reinforcing the efficacy of stem cells, including ethionamide, a method of reinforcing the efficacy of stem cells, including culturing stem cells in the medium composition, a method of preparing stem cells with reinforced efficacy, stem cells prepared by the above-mentioned method, and a use thereof. According to the present invention, the anti-inflammatory effect of mesenchymal stem cells and expression levels of paracrine factors may be effectively improved by a simple method of treating mesenchymal stem cells with ethionamide, and the stem cells obtained by the above method may be effectively used for preventing or treating an inflammatory disease or a degenerative brain disease.Type: GrantFiled: July 15, 2020Date of Patent: April 2, 2024Assignee: SAMSUNG LIFE PUBLIC WELFARE FOUNDATIONInventors: Duk Lyul Na, Jong Wook Chang, Hyo Jin Son
-
Patent number: 11918687Abstract: Disclosed herein are compositions comprising isolated exosomes, for instance exosomes wherein at least 20% of the exosomes comprise SDC2, methods of isolation, and methods of use.Type: GrantFiled: January 13, 2017Date of Patent: March 5, 2024Assignee: ORBSEN THERAPEUTICS LIMITEDInventors: Stephen J. Elliman, Jack Kavanaugh, Larry Couture
-
Patent number: 11911450Abstract: The invention provides a method of treating or preventing pain in a subject in need thereof. The method comprising administering to the subject an expression vector comprising a nucleic acid sequence encoding carbonic anhydrase (10) or carbonic anhydrase (11) such that the nucleic acid is expressed to produce carbonic anhydrase (10) or carbonic anhydrase (11). Alternatively, the method comprising administering to the subject an expression vector comprising a nucleic acid sequence encoding a carbonic anhydrase (8) fragment such that the nucleic acid is expressed to produce the carbonic anhydrase (8) fragment.Type: GrantFiled: July 13, 2018Date of Patent: February 27, 2024Assignee: UNIVERSITY OF MIAMIInventors: Roy Levitt, Gerald Z. Zhuang
-
Patent number: 11913020Abstract: The present invention relates to a medium composition for improving stem cell migration, which includes ethionamide, and a use thereof. According to the present invention, the migration of stem cells may be effectively improved by the adjustment of a culture environment, which is a simple and safe method, without using gene manipulation or a viral vector, and the stem cells improved in migration by the method may be effectively used as a stem cell therapeutic agent that is able to function by rapidly migrating to the damaged region after transplantation.Type: GrantFiled: October 8, 2018Date of Patent: February 27, 2024Assignee: SAMSUNG LIFE PUBLIC WELFARE FOUNDATIONInventors: Duk Lyul Na, Jong Wook Chang, Hyo Jin Son
-
Patent number: 11891615Abstract: A method of producing Klotho protein includes preparing a Klotho plasmid DNA vector, culturing cells, transfecting the cells with the Klotho plasmid DNA vector in a cell culture medium, growing the transfected cells, and harvesting the cell culture supernatant by removing the transfected cells. The Klotho plasmid DNA vector has a mammalian selection marker and a Klotho open reading frame. The cells are primary fibroblast cells and/or mesenchymal stromal cells. A method of manufacturing a cosmetic composition includes combining Klotho protein or the cell culture supernatant with a cosmetically acceptable vehicle. A method of treating a patient to improve the condition and appearance of aging skin includes topically administering the cosmetic composition to the patient. By upregulating the Klotho gene in vitro and incorporating the Klotho protein and growth factors into a composition, transepidermal water loss, skin atrophy, and free radical damage to the skin may be addressed.Type: GrantFiled: April 9, 2021Date of Patent: February 6, 2024Inventor: Gail Marion Humble
-
Patent number: 11891616Abstract: The present disclosure provides methods and compositions for the treatment of diseases and genetic disorders linked to MeCP2 loss and/or misfunction, including RETT syndrome. The methods and compositions of the present disclosure comprise rAAV vectors and rAAV viral vectors comprising transgene nucleic acid molecules comprising nucleic acid sequences encoding for a MeCP2 polypeptide.Type: GrantFiled: December 4, 2020Date of Patent: February 6, 2024Assignee: Board of Regents of the University of Texas SystemInventors: Steven J. Gray, Sarah Sinnett
-
Patent number: 11857575Abstract: The invention relates to exosomes derived from mesenchymal stem cells and well as isolated populations of said exosomes and method for preparing said isolated exosome populations. The invention also relates to a pharmaceutical composition comprising said exosome or isolated exosome population and their use in a method of treating an immune-mediated inflammatory disease in a subject.Type: GrantFiled: November 2, 2016Date of Patent: January 2, 2024Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Olga De La Rosa, Eleuterio Lombardo, Wilfried Dalemans, Javier Garcia Casado, Rebeca Blazquez Duran, Francisco Miguel Sanchez Margallo
-
Patent number: 11834640Abstract: Disclosed are devices for improving viability of isolated islets or ?-cells and stimulating insulin production from isolated islets or ?-cells and uses thereof for treating type 1 diabetes.Type: GrantFiled: September 15, 2020Date of Patent: December 5, 2023Assignee: Board of Regents, The University of Texas SystemInventors: Michael Cho, Caleb Liebman
-
Patent number: 11826386Abstract: Disclosed are compositions and methods for targeted treatment of cancer. The present disclosure provides chimeric antigen receptors and cells expressing such chimeric antigen receptors. In certain embodiments, engineered cells expressing the chimeric antigen receptors are specific for a low density cancer antigen or peptide in groove antigen.Type: GrantFiled: May 4, 2021Date of Patent: November 28, 2023Assignee: Regeneron Pharmaceuticals, Inc.Inventors: David DiLillo, Thomas Craig Meagher
-
Patent number: 11819554Abstract: The disclosure relates to methods and compositions for reactivating a silenced FMR1 gene. In some aspects, methods described by the disclosure are useful for treating a FMR1-inactivation-associated disorder (e.g., fragile X syndrome).Type: GrantFiled: September 16, 2016Date of Patent: November 21, 2023Assignees: UNIVERSITY OF MASSACHUSETTS, FULCRUM THERAPEUTICS, INC.Inventors: Michael R. Green, Minggang Fang, Walter Kowtoniuk
-
Patent number: 11806442Abstract: Periosteum harvesting and processing systems and methods enable rapid, efficient, and repeatable harvesting of periosteum tissue from human long bones and processing of the tissue into individual fibers for use in strengthening surgical allograft products. One harvesting and processing method involves providing a human long bone, securing the long bone between two rotating live centers, scraping, using one of a plurality of harvesting tools selected from a harvesting and processing kit, periosteum tissue from the long bone, executing a first wash cycle comprising a hydrogen peroxide wash, executing a second wash cycle comprising an isopropyl alcohol wash, executing a third wash cycle comprising a phosphate buffered saline wash, compressing the periosteum tissue to remove excess fluid, cryofracturing the tissue until a desired fiber size is achieved, and separating the periosteum tissue into individual periosteum fibers having the desired fiber size. Other embodiments are also disclosed.Type: GrantFiled: September 16, 2019Date of Patent: November 7, 2023Assignee: AllosourceInventors: Megan Maccagnan, Cameron Mattson, Cole Watkins, Adrian C. Samaniego, William Maslanik
-
Patent number: 11795475Abstract: Provided are a cell strain HEK293.CS for reducing the production of a replication competent adenovirus, and a construction method and the use thereof. HEK293.CS is a safe adenovirus-producing cell line constructed by knocking out a gene fragment homologous to the Ad5 adenovirus E1 gene in HEK293 and providing a template plasmid to replace said gene fragment with a non-homologous sequence that stabilizes the expression of the E1 gene. Compared with the unmodified HEK293 cell strain, HEK293.CS shows no decrease in growth ability and virus production ability, but does not produce a detectable RCA. HEK293.CS can be used for the mass culture of a recombinant human type 5 adenovirus, and reducing the probability of RCA production in the manufacture process of drugs such as vaccines and antibodies.Type: GrantFiled: March 2, 2020Date of Patent: October 24, 2023Assignee: CANSINO BIOLOGICS INC.Inventors: Tao Zhu, Haiyan Cui, Weiwei Chen, Lei Duan, Junqiang Li, Jin Ma, Chunlin Xin, Zhongqi Shao, Xuefeng Yu, Huihua Mao
-
Patent number: 11718823Abstract: The present disclosure relates to a novel method for rapid preparation of three dimensional (3D) spheroids/organoids, and the 3D spheroids/organoids prepared by the novel method.Type: GrantFiled: December 1, 2020Date of Patent: August 8, 2023Assignee: Purdue Research FoundationInventors: Bumsoo Han, George Tsu-Chih Chiu, Cih Cheng
-
Patent number: 11634675Abstract: The present invention relates to an insertable culture container and a kit for three-dimensional cell culture, and a three-dimensional cell co-culture method using the same, the insertable culture container for three-dimensional cell culture comprising: a cylindrical side wall having open upper and lower portions; at least one hook protruding outward from the upper side of the side wall; and at least one support protruding inward from the lower side of the side wall. The present invention is advantageous in that air required for a three-dimensional cell culture structure can be smoothly supplied since the cell is cultured at a position spaced apart from a bottom surface of the culture container, and an existing culture plate can be used without change due to the culture container configured as an insert type.Type: GrantFiled: December 7, 2018Date of Patent: April 25, 2023Assignees: KOREA INSTITUTE OF INDUSTRIAL TECHNOLOGY, CEFO CO., LTD.Inventors: Dongmok Lee, Hyunsook Park, Sunray Lee